ERBB2 and glioblastoma: In contrast, no HER2 amplification was detected by NGS in 382 patients with sarcomas, 224 patients with glioblastomas, 132 patients with thyroid cancers, 97 patients with renal cell carcinomas, 66 patients with neuroendocrine tumors, 50 patients with lymphoma, and 37 patients with appendiceal carcinoma.